Boltezar Lucka, Pintaric Karlo, Pretnar Jože, Pohar Perme Maja, Novakovic Barbara Jezersek
Department of Medical Oncology, Institute of Oncology Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Slovenia.
Radiol Oncol. 2016 Jun 24;51(1):81-87. doi: 10.1515/raon-2016-0040. eCollection 2017 Mar 1.
Advanced follicular lymphoma (FL) and mantle cell lymphoma (MCL) are incurable diseases with conventional treatment. The high dose treatment (HDT) with autologous stem cell transplantation (ASCT), however, offers a certain proportion of these patients the prospect of a prolonged disease-free and overall survival. The aim of this study was to investigate the event free survival (EFS) and overall survival (OS) in patients with FL and MCL treated with ASCT.
Seventeen patients with FL and 29 patients with MCL were included, 15 of them were transplanted to consolidate the response to second line treatment and 24 to consolidate their first remission, respectively. All were conditioned with total body irradiation (TBI) and high dose cyclophosphamide between 2006 and 2014 and all were transplanted with peripheral blood stem cells.
The estimated 5-year OS for FL was 87.8% (95% confidence interval [CI] 59.5%-96.8%) and for MCL 79.3% (95% CI 56.1%-91.1%), respectively. The estimated 5-year EFS for FL was 76.0% (95% CI 48.0%-90.3%) and for MCL 69.8% (95% CI 45.5%-84.8%), respectively. There were no secondary hematological malignancies observed in either group.
Based on above results, the ASCT with TBI is a good treatment option in terms of long-term survival for patients with follicular and mantle cell lymphoma demonstrating a relatively low rate of late toxicities and secondary malignancies.
晚期滤泡性淋巴瘤（FL）和套细胞淋巴瘤（MCL）采用传统治疗方法无法治愈。然而，自体干细胞移植（ASCT）的高剂量治疗（HDT）为这些患者中的一定比例提供了延长无病生存期和总生存期的前景。本研究的目的是调查接受ASCT治疗的FL和MCL患者的无事件生存期（EFS）和总生存期（OS）。
纳入17例FL患者和29例MCL患者，其中15例分别接受移植以巩固对二线治疗的反应，24例接受移植以巩固首次缓解。所有患者在2006年至2014年间均接受全身照射（TBI）和高剂量环磷酰胺预处理，均采用外周血干细胞进行移植。
FL患者的估计5年总生存率为87.8%（95%置信区间[CI]59.5%-96.8%），MCL患者为79.3%（95%CI 56.1%-91.1%）。FL患者的估计5年无事件生存率为76.0%（95%CI 48.0%-90.3%），MCL患者为69.8%（95%CI 45.5%-84.8%）。两组均未观察到继发性血液系统恶性肿瘤。
基于上述结果，对于滤泡性和套细胞淋巴瘤患者，TBI联合ASCT在长期生存方面是一种较好的治疗选择，晚期毒性和继发性恶性肿瘤发生率相对较低。
